Anders Waage
#161,529
Most Influential Person Now
Researcher
Anders Waage's AcademicInfluence.com Rankings
Anders Waagecomputer-science Degrees
Computer Science
#9332
World Rank
#9805
Historical Rank
Machine Learning
#4055
World Rank
#4104
Historical Rank
Artificial Intelligence
#4394
World Rank
#4455
Historical Rank
Database
#6301
World Rank
#6533
Historical Rank
Download Badge
Computer Science
Anders Waage's Degrees
- PhD Computer Science Norwegian University of Science and Technology
Similar Degrees You Can Earn
Why Is Anders Waage Influential?
(Suggest an Edit or Addition)Anders Waage's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome (1989) (1202)
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE (1987) (1132)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma (2015) (690)
- Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response (1989) (445)
- Inflammatory Response After Open Heart Surgery: Release of Heat-Shock Protein 70 and Signaling Through Toll-Like Receptor-4 (2002) (397)
- Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
- Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo (1989) (293)
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. (2011) (261)
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. (2002) (254)
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. (2009) (235)
- Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. (2010) (234)
- Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts (1990) (226)
- Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. (1988) (222)
- IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
- Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. (1987) (191)
- Interleukin-21 is a growth and survival factor for human myeloma cells. (2002) (179)
- Cytokine regulation of interleukin 6 production by human endothelial cells. (1989) (177)
- Elevated Plasma Levels of Tumor Necrosis Factor (TNF)-α, Soluble TNF Receptors, Interleukin (IL)-6, and IL-IO in Patients with Hemorrhagic Fever with Renal Syndrome (1996) (170)
- LOCAL PRODUCTION OF TUMOR NECROSIS FACTOR a (1989) (165)
- Addiction to c-MYC in multiple myeloma. (2012) (149)
- Concomitant Expression of Hepatocyte Growth Factor/Scatter Factor and the Receptor c-MET in Human Myeloma Cell Lines* (1996) (148)
- Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial (2015) (146)
- High levels of interleukin 10 in serum are associated with fatality in meningococcal disease (1995) (144)
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud (2020) (144)
- Genome-wide association study identifies multiple susceptibility loci for multiple myeloma (2016) (136)
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. (2013) (133)
- Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients (1986) (132)
- UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M‐proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) (2009) (131)
- Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells (2004) (121)
- The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network (2014) (120)
- Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. (1993) (115)
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group (2017) (112)
- Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B (2015) (111)
- Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice (1992) (109)
- Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. (2010) (109)
- Pulmonary embolism: detection with MR perfusion imaging of lung--a feasibility study. (1997) (106)
- Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. (1996) (104)
- Activation of adult human derived microglia by myelin phagocytosis in vitro (1994) (104)
- A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells (2004) (100)
- Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. (2008) (100)
- Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. (2016) (97)
- Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. (2002) (84)
- Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis (2003) (84)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (81)
- Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. (2004) (80)
- TNF and IL‐6 are potent growth factors for OH‐2, a novel human myeloma cell line (1994) (80)
- Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice (2016) (79)
- TNF receptors in murine Candida albicans infection: evidence for an important role of TNF receptor p55 in antifungal defense. (1996) (79)
- Plasma homocysteine levels in patients with deep venous thrombosis. (1995) (79)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- Regulation of interleukin-2 and interleukin-6 production from T-cells: Involvement of interleukin-1 β and transforming growth factor-β (1990) (77)
- Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production (1990) (76)
- Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency Mice (1999) (75)
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (2013) (73)
- PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy (2015) (72)
- Perfusion abnormalities in pulmonary embolism studied with perfusion MRI and ventilation‐perfusion scintigraphy: An intra‐modality and inter‐modality agreement study (2002) (66)
- Interleukin‐1, interleukin‐6 and tumor necrosis factor at delivery in preeclamptic disorders (1995) (65)
- Antigen presentation by human fetal astrocytes with the cooperative effect of microglia or the microglial-derived cytokine IL-1 (1995) (65)
- Lack of IL‐1 secretion from human myeloma cells highly purified by immunomagnetic separation (1993) (65)
- Current understanding of the pathogenesis of gram-negative shock. (1991) (62)
- Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. (1989) (58)
- Magnesium deficiency diagnosed by an intravenous loading test. (1992) (57)
- Different Role of Cytokine Mediators in Septic Shock Related to Meningococcal Disease and Surgery/Polytrauma (1992) (57)
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
- Hepatocyte growth factor in myeloma patients treated with high‐dose chemotherapy (2002) (57)
- Effects of Polysaccharide Fucoidin on Cerebrospinal Fluid Interleukin-1 and Tumor Necrosis Factor Alpha in Pneumococcal Meningitis in the Rabbit (1999) (55)
- Cytokine mediators of septic infections in the normal and granulocytopenic host (1993) (55)
- p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. (1992) (53)
- Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. (2005) (52)
- c-Met signaling promotes IL-6-induced myeloma cell proliferation (2009) (49)
- Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease (1999) (48)
- Perfusion magnetic resonance imaging of the lung: Characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study (2000) (48)
- Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade (2020) (47)
- Monitoring multiple myeloma by quantification of recurrent mutations in serum (2017) (47)
- Hepatocyte growth factor promotes migration of human myeloma cells (2008) (47)
- High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence (2016) (46)
- Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial. (2007) (46)
- Abnormal adipokine levels and leptin‐induced changes in gene expression profiles in multiple myeloma (2009) (45)
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report (2021) (44)
- The inflammatory response following treatment of abdominal aortic aneurysms: a comparison between open surgery and endovascular repair. (2000) (44)
- Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. (2017) (44)
- Therapy-related acute promyelocytic leukemia with t(15;17) (q22;ql2) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature (1995) (42)
- High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis (2009) (40)
- Interleukin‐15 blocks apoptosis and induces proliferation of the human myeloma cell line OH‐2 and freshly isolated myeloma cells (1999) (40)
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
- Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients (2018) (39)
- Health-related quality of life in patients with multiple myeloma - does it matter? (2015) (38)
- Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project (2022) (38)
- Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease (2015) (36)
- A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity (2008) (36)
- Proteasome inhibitors and IMiDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21 (2016) (36)
- Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells (2000) (35)
- A Gain‐of‐Function Mutation in EPO in Familial Erythrocytosis (2018) (34)
- Early response predicts thalidomide efficiency in patients with advanced multiple myeloma * (2004) (34)
- Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate (2013) (33)
- Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT (2015) (33)
- Cytokine-associated tissue injury and lethality in mice: a comparative study. (1991) (33)
- Interleukin 8 in serum in granulocytopenic patients with infections (1994) (33)
- BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis (2015) (32)
- Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial (2009) (30)
- The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells (2016) (30)
- Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. (1995) (30)
- Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells (2016) (29)
- Apoptosis, proliferation and NF‐κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH‐2: amplification of Fas‐mediated apoptosis by tumor necrosis factor (1999) (28)
- Reactivation of hepatitis B virus infectionin an anti‐HBc and anti‐HBs positivepatient after allogeneic bone marrow transplantation (2000) (27)
- A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal Cells (2012) (26)
- Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals (1999) (26)
- HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. (2013) (26)
- Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin‐6 in serum in granulocytopenic patients with fever (1995) (26)
- MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials. (2010) (25)
- Hereditary Haemochromatosis in Two Cousins with Cluster Headache (2002) (24)
- Compartmentalization of TNF and IL-6 in meningitis and septic shock (1993) (24)
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study (2014) (23)
- Role of hepatocyte growth factor and its receptorc-met in multiple myeloma (1998) (23)
- PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients (2018) (23)
- A Phase II Study of PXD101 in Advanced Multiple Myeloma. (2006) (23)
- Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017 (2020) (23)
- CYTOKINE RESPONSE PATTERN IN SWEET'S SYNDROME ASSOCIATED WITH MYELODYSPLASIA (1994) (22)
- Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. (2018) (22)
- Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomised phase III trial (2011) (22)
- The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression (2018) (22)
- Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. (2000) (20)
- The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications (2014) (20)
- A closed-chest pulmonary artery occlusion/reperfusion model in the pig: detection of experimental pulmonary embolism with MR angiography and perfusion MR imaging. (2000) (19)
- Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma (2015) (19)
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients (2018) (19)
- Activin A inhibits BMP-signaling by binding ACVR 2 A and ACVR 2 B (2015) (19)
- The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma (2015) (19)
- Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma (2019) (19)
- Direct evidence for a polygenic etiology in familial multiple myeloma. (2017) (18)
- Regulation of interleukin-2 and interleukin-6 production from T-cells: involvement of interleukin-1 beta and transforming growth factor-beta. (1990) (18)
- Soluble c‐Met in serum of patients with multiple myeloma: correlation with clinical parameters (2011) (18)
- MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy (2015) (18)
- Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. (2020) (17)
- Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study (2019) (17)
- Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. (1995) (17)
- European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma (2010) (16)
- A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (2020) (15)
- Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities (2020) (15)
- Tumour necrosis factor and septic shock (1998) (14)
- Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease. (1998) (14)
- Immunohistochemical analysis of hepatocyte growth factor and c‐Met in plasma cell disease (2012) (13)
- Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro (2016) (13)
- Release of bioactive interleukin 6 but not of tumour necrosis factor-α after elective cardiopulmonary bypass (1993) (13)
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma (2021) (13)
- Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study (2020) (13)
- Congenital thrombotic thrombocytopenic purpura. (2016) (12)
- FGFR3 is expressed and is important for survival in INA‐6, a human myeloma cell line without a t(4;14) (2009) (12)
- Severe human septic shock involves more than tumor necrosis factor. (1991) (12)
- Monoclonal immunoglobulins promote bone loss in multiple myeloma. (2020) (12)
- Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients (2014) (12)
- VOLIN and KJON—Two novel hyperdiploid myeloma cell lines (2016) (12)
- Why do myeloma patients have bone disease? A historical perspective. (2019) (11)
- Bone diesease in multiple myeloma (2006) (11)
- Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
- The Cytokine Network in Trauma and Sepsis I: TNF and IL-8 (1993) (9)
- The influence of growth hormone on tumour necrosis factor and neutrophil leukocyte function in sepsis. (1997) (9)
- Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis (2020) (9)
- Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia (2016) (9)
- Long‐term outcomes of patients treated with rituximab as second‐line treatment for adult immune thrombocytopenia – Follow‐up of the RITP study (2020) (8)
- MyelomA Genetics International Consortium (2012) (8)
- The Cytokine Network in Sepsis II: IL-1 and IL-6 (1993) (8)
- JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR (2018) (8)
- Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression (2015) (8)
- Effect of Pentoxifylline and HWA 138 on Production of Tumor Necrosis and Interleukin 6 From Monocytes (1990) (8)
- Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence (2022) (8)
- A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma. (2004) (7)
- Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes (2018) (7)
- Acute leukemia in middle Norway 1984-88. (1994) (7)
- Lack of endotoxin tolerance with respect to TNFα production in the subarachnoid space (2000) (7)
- Non-signaling functions of TNF-R75: findings in man and mouse. (1994) (7)
- Thrombotic thrombocytopenic purpura in 2 siblings: defective platelet function and plasma factor deficiency occurring simultaneously. (2009) (6)
- Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma. (2015) (6)
- Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients (2014) (6)
- Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma (2022) (5)
- CHRONIC GRANULOCYTIC LEUKAEMIA IN ACCELERATED STAGE TREATED WITH LOW DOSE CYTOSINE ARABINOSIDE (1985) (5)
- ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study. (2015) (5)
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). (2013) (5)
- p 55 and p 75 Tumor Necrosis Factor Receptors in Patients With Chronic Lymphocytic Leukemia (2003) (5)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (4)
- Effects of a combined drug regimen on tumour necrosis factor and plasma kallikrein activity in experimental endotoxaemia. (1994) (4)
- Germline variants at SOHLH2 influence multiple myeloma risk (2021) (4)
- Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells (2021) (4)
- Lack of endotoxin tolerance with respect to TNF alpha production in the subarachnoid space. (2000) (4)
- The involvement of tumor necrosis factor-alpha (TNF-alpha) in immunomodulation and in septic shock. (1988) (4)
- Growth differentiation factor 15 ( GDF 15 ) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF 15 levels are associated with multiple myeloma bone disease (2015) (3)
- Mp Versus Mpt for Previously Untreated Elderly Patientswith Multiple Myeloma: A Meta Analysis of Survival of 1682individual Patient Data From 6 Randomized Clinical Trials (2010) (3)
- Mn2+ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF‐1, and SDF‐1α (2008) (3)
- Epidemiology of Myeloproliferative Neoplasms in Norway (2014) (3)
- Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma. (2007) (3)
- Functional dissection of inherited non-coding variation influencing multiple myeloma risk (2022) (3)
- Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study – The Ritp Study (NCT00344149) (2013) (3)
- Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango? (2021) (3)
- A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group (2019) (3)
- Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study (2019) (2)
- Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform (2019) (2)
- Gene expression classifier EMC92/SKY92 and revised ISS robustly identify high-risk multiple myeloma in elderly patients of the HOVON-87/NMSG-18 study (2017) (2)
- IL-32 is a metabolic regulator promoting survival and proliferation of malignant plasma cells (2021) (2)
- Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group (2017) (2)
- Patterns of previous and secondary malignancies in patients with multiple myeloma (2021) (2)
- Chemical, physical and biological factors triggering Bcl-xL-mediated apoptosis (2020) (2)
- Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. (2006) (2)
- Glucocorticoids suppresstheproduction oftumournecrosis factor bylipopolysaccharide-stimulated humanmonocytes (1988) (2)
- Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients (2015) (2)
- PS1374 PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS (2019) (2)
- Detection and Monitoring of BRAF and NRAS Mutant Clones in Myeloma Patients By Digital PCR of Circulating DNA (2015) (2)
- [Thalidomide--a dreaded drug with new indications]. (2001) (2)
- The SKY92 prognostic marker is validated in eight multiple myeloma clinical datasets (2016) (2)
- Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study (2017) (2)
- PDL 1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD 1-PDL 1 Therapy (2015) (2)
- Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group (2021) (2)
- A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (2020) (1)
- THE REVII TRIAL : LENALIDOMIDE AND DEXAMETHASONE AS SECOND LINE TREATMENT IN MYELOMA FOLLOWED BY EXTENDED LENALIDOMID VS LEN/DEX (2015) (1)
- Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple myeloma (2019) (1)
- Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups (2015) (1)
- Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy (2018) (1)
- lymphocytic leukemia p55 and p75 tumor necrosis factor receptors in patients with chronic (2011) (1)
- Tumor Necrosis Factor, Interleukin-1, and Interleukin-6 in Meningococcal Disease (1990) (1)
- Clinical and Biological Implications of BRAF V600E Mutation in Multiple Myeloma (2014) (1)
- The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression (2018) (1)
- Is a deep response the key to successful treatment of multiple myeloma (2015) (1)
- SMOKING AND POLYCYTHAEMIA (1987) (1)
- Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis (2014) (1)
- Effect of pyridoxine on tumor necrosis factor activitiesin vitro (1992) (1)
- [Tumor necrosis factor. A mediator in septic shock]. (1988) (1)
- The role of cytokines in the pathogenesis of Neisseria meningitidis infection (1996) (1)
- Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma: results of the HOVON87/NMSG18 study (2017) (1)
- Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival (2022) (1)
- metastasis-associated phosphatase PRL-3 in human myeloma cells Overexpression and involvement in migration by the (2013) (1)
- High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling (2020) (1)
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report (2021) (1)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (1)
- P-079: Altered composition of CD8 T cells subsets over time in the bone marrow of multiple myeloma patients with long- and short-term disease control (2022) (1)
- Risk of multiple myeloma and other malignancies among first‐ and second‐degree relatives of patients with multiple myeloma: A population‐based study (2022) (1)
- Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler (2014) (1)
- European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib (2016) (1)
- Incidence and Survival of Multiple Myeloma; A Population-Based Study on 10 961 Patients Diagnosed 1982-2017 (2019) (1)
- TNF receptor P75 on a myeloma cell line is sensitive to TNF, but not to lymphotoxinα (LTα) (1994) (0)
- Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes (2018) (0)
- Trial efficacy vs real world effectiveness in first line treatment of multiple myeloma (2015) (0)
- Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients (2014) (0)
- Risk of multiple myeloma and other malignancies among first‐and second‐degree relatives of patients with multiple myeloma: A population‐based study (2022) (0)
- [High dose therapy with autologous stem cell support--finally a progress in myelomatosis]. (2001) (0)
- Carfilzomib-Cyclophosphamide-Dexamethasone induction and salvage ASCT transplant-eligible multiple myeloma with firs trelapse after upfront ASCT (2018) (0)
- Immunosuppressive adenosine - a novel treatment target for multiple myeloma (2019) (0)
- Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial (2022) (0)
- GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels are Associated with Multiple Myeloma Bone Disease (2014) (0)
- Health-Related Quality of Life in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Either Thalidomide or Lenalidomide-Based Regimen Until Progression (HOVON-87/NMSG18 Study): A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Study (2019) (0)
- Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC). (2018) (0)
- P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13 (2022) (0)
- Abstract 5023: Multiple myeloma with a clonal del17p aberration is characterized by somatic TP53 mutations, which negatively affect prognosis in this cytogenetic subgroup (2016) (0)
- A Selective Inhibitor of c-Met Blocks an Autocrine HGF Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells. (2004) (0)
- [New York, 11 September 2001]. (2001) (0)
- Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk (2022) (0)
- Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study (2019) (0)
- Unexpected High Frequency of Upshaw-Schulman Syndrome in Norway (2012) (0)
- [In hundred years everything will be known]. (2007) (0)
- Risk stratification by SKY92+ISS outperforms ifish markers t(4;14) and del(17p) in multiple myeloma (2016) (0)
- S1602 CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION (2019) (0)
- Tumor Necrosis Factor Receptors in Patients With Chronic Lymphocytic Leukemia (1992) (0)
- IL-6 and IGF-1 Act in Synergy with HGF in Myeloma Cells by Modulating the Ras-MAPK Pathway. (2007) (0)
- Tumor Necrosis Factor in Infection and Leukemia (1993) (0)
- Abstract 1768: Chloroquine potentiates carfilzomib but not bortezomib effects on myeloma cells (2015) (0)
- Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma (2019) (0)
- [Tumor necrosis factor]. (1988) (0)
- Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse (2018) (0)
- HGF - c-Met interaction with syndecan-1 in lipid rafts promotes Akt signaling in myeloma cells (2013) (0)
- European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT) (2017) (0)
- IL-6, IGF-1 and IL-21 Act in Synergy with HGF in Myeloma Cells by Inducing the HGF-Receptor c-Met. (2006) (0)
- Bmps(Bone Morphogenetic Proteins) Inhibit Growth in Multiple Myeloma Cells by p53 Activation. (2004) (0)
- Induction of Cyclin D1 by HGF, IGF-1 and IL-6 in a Human Myeloma Cell Line with a t(11:14) Translocation. (2006) (0)
- Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial (2014) (0)
- Syddansk Universitet Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma a study of the International Myeloma Working (2017) (0)
- Tumour Necrosis Factor in Human Septicaemia (1988) (0)
- [Research takes time]. (2018) (0)
- Can overall survival be improved in elderly multiple myeloma patients (2015) (0)
- Abstract 2351: MYC gene copy number determine MYC expression and sensitivity to a MYC-inhibitor in multiple myeloma cells (2014) (0)
- Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B (2015) (0)
- B608 Syndecan-1 Mediates HGF/c-Met Endocytosis and Signaling in Myeloma Cells (2009) (0)
- P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients (2022) (0)
- Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial (1987) (0)
- P-030: Regular monitoring with whole body low-dose CT for osteolysis in multiple myeloma reveals more cases of progressive bone disease than imaging performed by clinical indication (2022) (0)
- [Recommendation to uncritical use of granulocyte colony-stimulating factor (G-CSF)?]. (1992) (0)
- [Behavior of hypertension and cardiovascular findings in hypertension within an observation period of 10 years (the Wurzen study 1961-1971)]. (1978) (0)
- Abstract 3130: Dependency on c-MYC in multiple myeloma. (2013) (0)
- Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines (2022) (0)
- B304 Does Toll-like Receptor 9 Signaling Play a Role in Myeloma Disease Progression? (2009) (0)
- [Cancer--the inner enemy]. (2003) (0)
- Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial (2022) (0)
- Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma (2015) (0)
- Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (2020) (0)
- Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation: data from a Nordic phase II trial (2018) (0)
- [Polycythemia and smoking]. (1987) (0)
- HGF promotes IL-6 and IGF-1 signalling in multiple myeloma cells (2007) (0)
- A Gain-of-Function Mutation in EPO Gene Causes Familial Erythrocytosis (2017) (0)
- Genetic aberrations in Norwegian myeloma patients -a study based on interphase FISH on newly diagnosed patients from 2006-2008 (2009) (0)
- Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis (2016) (0)
- Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. (2006) (0)
- Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark (2019) (0)
- with lytic bone disease Serum osteoprotegerin levels are reduced in patients with multiple myeloma (2013) (0)
- B127 FGFR3 Expression Is Important in the t(4;14)neg INA-6 HMCL (2009) (0)
- Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis (2015) (0)
- Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk (2021) (0)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (0)
- Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma (2018) (0)
- Contents Vol. 133, 2015 (2015) (0)
- [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine]. (1986) (0)
- [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients]. (2011) (0)
- A method to identify physical, chemical and biological factors that trigger Bcl-xL-mediated apoptosis (2020) (0)
- Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups, (2011) (0)
- [Sarcoidosis of the nervous system]. (1986) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Anders Waage?
Anders Waage is affiliated with the following schools:
